Targeting the MET pathway in advanced NSCLC has been of particular interest due to its
role as both a primary oncogenic driver and secondary oncogenic driver of acquired …

MET proto-oncogene (MET) alterations are known driver oncogenes in non-small cell lung
cancer (NSCLC). Since the identification of MET as a potential therapeutic target, extensive …

Targeted therapies have revolutionized the treatment and improved the outcome for
oncogene-driven NSCLC and an increasing number of oncogenic driver therapies have …

Lung cancer classification has been radically transformed in recent years as genomic
profiling has identified multiple novel therapeutic targets including MET exon 14 (METex14) …

Lung cancer is the leading cause of death for solid tumors worldwide with an annual
mortality of over one million. Lung carcinoma includes a series of different diseases which …

The receptor tyrosine kinase, Met, orchestrates a complex signalling network that
physiologically drives a programme of 'invasive growth'. In cancer however, this process …

The hepatocyte growth factor receptor (MET) is a potential therapeutic target in a number of
cancers, including NSCLC. In NSCLC, MET pathway activation is thought to occur through a …

The c-MET proto-oncogene (MET) plays an important role in lung oncogenesis, affecting
cancer-cell survival, growth and invasiveness. The MET receptor in non-small–cell lung …

Highlights•Understanding mechanisms of resistance in oncogene-driven lung cancer is
crucial.•MET amplification is a recurrent driver of resistance, across molecularly defined …

Targeting somatically activated oncogenes has revolutionized the treatment of non–small
cell lung cancer (NSCLC). Mutations in the gene mesenchymal–epithelial transition (MET) …